Observational studyThe Journal of allergy and clinical immunology2024

Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity.

Martin C Runnstrom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.